Interviews

headshot Stefano Cottignoli, senior vice president and head of global business and development at Chiesi
Partnering
Chiesi’s partnering success: Confessions of a mid-sized pharmaChiesi’s partnering success: Confessions of a mid-sized pharma

Chiesi Group’s SVP tells BioXconomy how this Italian family-owned company has navigated global expansions, developed strategic partnerships, and developed sustainable business practices.

Nov 14, 2024
|
6 Min Read
Green leaf with sustainability symbol
Business Strategy
The sustainability series: Reflect, rethink, and reformThe sustainability series: Reflect, rethink, and reform
byMillie Nelson
Oct 11, 2024
14 Min Read
CEO of Poseida, Kristin Yarema
Business Strategy
Poseida: New CEO, same passion for allogeneic therapiesPoseida: New CEO, same passion for allogeneic therapies
byMillie Nelson
Feb 26, 2024
7 Min Read
Sand timer
Business Strategy
Testing times: MilliporeSigma talks CDMO competitionTesting times: MilliporeSigma talks CDMO competition
byMillie Nelson
Oct 11, 2023
3 Min Read

BIO-EUROPE COVERAGE

Novo Nordisk sign
Business Strategy
Lessons and blessings: The Novo Nordisk way
Lessons and blessings: The Novo Nordisk way
Michael May, PhD, President, CCRM discusses Canada as a place for life sciences in this video.
Hubs
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Bridging AI & Life Sciences, Why Investing in Canada Should Be Your Next Move
Shaking hands
Partnering
Picky pharma prone to better proven partners amid dealmaking downturn
Picky pharma prone to better proven partners amid dealmaking downturn
Hervé Ansanay, Biotech Alliance Manager, discusses the features of the RESEAU SATT - SATT NETWORK
Hubs
RESEAU SATT, the Best of French Deep Tech
RESEAU SATT, the Best of French Deep Tech
Jan 13 - Jan 15, 2025
An all-inclusive healthcare conference at Hilton Union Square, San Francisco
Register

Latest

Novo Nordisk logo on a window
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growth
Novo on the ‘ins and outs’ of its nucleic acid growth
dollar bills
Investment
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM 2025: J&J snaps up neuroscience biotech Intra-Cellular for $14.6bn
JPM written on wooden blocks in blue
Investment
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
JPM 2025: GSK shells out $1.15bn to buy oncology firm IDRx
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.
Stay Updated